Maloca, Peter M. http://orcid.org/0000-0002-4794-5859
,
Spaide, Richard F.
de Carvalho, Emanuel Ramos
Studer, Harald P.
W Hasler, Pascal
Scholl, Hendrik P. N.
Heeren, Tjebo F. C.
Schottenhamml, Julia
Balaskas, Konstantinos
Tufail, Adnan
Egan, Catherine
Article History
Received: 27 May 2019
Revised: 5 December 2019
Accepted: 19 December 2019
First Online: 6 January 2020
Compliance with ethical standards
:
: Peter Maloca is a consultant at ZEISS FORUM. Catherine Egan and Adnan Tufail received a financial grant from the National Institute for Health Research (NIHR) Biomedical Research Centre, based at Moorfields Eye Hospital, and also from the NHS Foundation Trust and the UCL Institute of Ophthalmology. Adnan Tufail is employed is a consultant for Heidelberg Engineering and Optovue. Richard Spaide and Peter Maloca are consultant for Topcon. Richard Spaide holds the patent for Frangi vessel segmentation. The funding organizations had no role in the design or conduct of the current study. The views expressed are those of the authors and not necessarily those of the National Eye Institute, the NHS, the NIHR, or the Department of Health.Dr. Hendrik Scholl is supported by the Foundation Fighting Blindness Clinical Research Institute (FFB CRI); Shulsky Foundation, New York, NY; National Centre of Competence in Research (NCCR) Molecular Systems Engineering (University of Basel and ETH Zürich); Swiss National Science Foundation; and Wellcome Trust.Dr. Scholl is a paid consultant of the following entities: Boehringer Ingelheim Pharma GmbH & Co. KG; Gerson Lehrman Group; and Guidepoint.Dr. Scholl is member of the Scientific Advisory Board of the Astellas Institute for Regenerative Medicine; Gensight Biologics; Intellia Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.; ReNeuron Group Plc/Ora Inc.; Pharma Research & Early Development (pRED) of F. Hoffmann-La Roche Ltd.; and Vision Medicines, Inc.Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of the following entities: Genentech Inc./F. Hoffmann-La Roche Ltd. and ReNeuron Group Plc/Ora Inc. Dr. Scholl is member of the steering committee of the following entities: Novo Nordisk (FOCUS trial).Dr. Scholl is co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which is constituted as a nonprofit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt.These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Johns Hopkins University and Bayer Pharma AG have an active research collaboration and option agreement. These arrangements have also been reviewed and approved by the University of Basel (Universitätsspital Basel, USB) in accordance with its conflict of interest policies.Dr. Hendrik Scholl is principal investigator of grants at the USB sponsored by the following entity: Acucela Inc.; Aegerion Pharmaceuticals (Novelion Therapeutics); Kinarus AG; NightstaRx Ltd.; Ophthotech Corporation; and Spark Therapeutics England, Ltd. Grants at USB are negotiated and administered by the institution (USB) which receives them on its proper accounts. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s).Others: None. This does not alter our adherence to Graefe’s policies on sharing data and materials. The mentioned institutions had no role in the design or conduct of this study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.